Inflammatix
Inflammatix develops rapid immune system diagnostics to improve patient care and public health.
About Inflammatix
Inflammatix develops novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system. It is a molecular diagnostics company developing rapid tests that read the immune system to resolve major clinical and public health challenges. They are initially focused on developing tests for acute bacterial and viral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University.
Company Facts
- Headquarters
- Burlingame
- Founded
- 2016
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00051_00100
- Funding Stage
- late_stage_venture
- Total Funding
- $194,799,923
- Last Funding Type
- series_e
- Last Funding Date
- 2024-09-12
- Website
- https://www.inflammatix.com
Industries & Categories
Bioinformatics, Biotechnology, Health Care, Health Diagnostics
Social Links
Canonical: https://fsome.com/organization/inflammatix-25390 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.